Bye, bye blockbusters, hello niche busters
R Collier - 2011 - Can Med Assoc
News news for countries such as Canada and the US, as even more clinical trials will move
to other countries where it is cheaper to conduct them. Even if their sales decline, drug …
to other countries where it is cheaper to conduct them. Even if their sales decline, drug …
Developing blockbuster drugs: both nature and nurture
LB Pont, J Keirsse, R Moss, P Poda, L Robke… - Nat Rev Drug …, 2021 - nature.com
Fig. 1| Intrinsic attributes of blockbusters. Four groups of drugs were defined as follows:
historical blockbusters, with peak-year sales (PYS)> US $2 billion in 2012 (n= 61); …
historical blockbusters, with peak-year sales (PYS)> US $2 billion in 2012 (n= 61); …
Are we living in the end of the blockbuster drug era?
B Debnath, LQ Al-Mawsawi, N Neamati - Drug news & perspectives, 2010 - europepmc.org
For the last two decades, we have seen remarkable growth in the pharmaceutical industry.
This growth has mainly been due to the approximately 100 new blockbuster drugs, such as …
This growth has mainly been due to the approximately 100 new blockbuster drugs, such as …
The'big pharma'dilemma: develop new drugs or promote existing ones?
D Weiss, P Naik, R Weiss - Nature reviews. Drug discovery, 2009 - nature.com
Pharmaceutical companies decide how much to invest in developing new drugs and
promoting existing ones, thereby influencing the rate of drug discovery and the state of …
promoting existing ones, thereby influencing the rate of drug discovery and the state of …
Blockbuster drug bows out
H Ledford - Nature, 2011 - nature.com
By 2000, pharmaceutical pipelines were filled with 'me too'drugs that offered low risk and a
quick route to approval, but only marginal improvement over drugs already available. As …
quick route to approval, but only marginal improvement over drugs already available. As …
[BOOK][B] The big fix: How the pharmaceutical industry rips off American consumers
K Greider - 2008 - books.google.com
As the pharmaceutical industry invests more and more in the development of new drugs,
true breakthroughs are few and far between. Into the breach comes a panoply of product …
true breakthroughs are few and far between. Into the breach comes a panoply of product …
Mega-trials for blockbusters
JPA Ioannidis - JAMA, 2013 - jamanetwork.com
THECONDUCTOFVERYLARGE, SIMPLETRIALS (MEGA-TRIALS) is uncommon and faces
several challenges, in particu-larcostanddifficultyinpatientrecruitment. However, these …
several challenges, in particu-larcostanddifficultyinpatientrecruitment. However, these …
Flacking for big pharma: Drugmakers don't just compromise doctors; they also undermine the top medical journals and skew the findings of medical research
HA Washington - The American Scholar, 2011 - JSTOR
" Drug Makers Cut Out Goodies for Doctors" and" Drugmakers Pulling Pens, Mugs & Pads"
read headlines in The New York Times and The Wall nal Health Blog at the end of 2008 …
read headlines in The New York Times and The Wall nal Health Blog at the end of 2008 …
Treatment access, health economics, and the wave of a magic wand
DJ Stewart, JP Bradford, G Batist - Current Oncology, 2022 - mdpi.com
New drugs are expensive, in part due to excessive drug development costs. Governments
are trying to reduce drug prices. This can delay access to effective agents. A country's …
are trying to reduce drug prices. This can delay access to effective agents. A country's …
[CITATION][C] As biotech drug prices surge, US is hunting for a solution
G Anand - Wall Street Journal, 2005
